Partnering from pre-clinical to product launch
-
Crystallisation, Solid State & Preformulation
Early solid state characterisation
Version (salt) screening & selection
Polymorph screening
Crystallisation design
Particle & formulation risk assessment for FTIH
Computational assessment using CCDC informatics tools
Micronisation assessment
Developability assessment
Preformulation including formulation definition for pre-clinical studies
Crystallisation development & optimisation
QbD process understanding & robustness
Control strategy for solid state & bulk properties
Comprehensive physical properties measurement capability
In-situ particle measurement & imaging
Filtration & washing optimisation
Why Choose CatSci?
Crystallisation and Solid State Expertise
Dr Robert Dennehy, our Director of Material Sciences leads our material sciences team. Robert has 20+ years of Large Pharma experience in the field of crystallisation and solid state of pharmaceuticals.
His industry experience and integrated approach to particle science and preformulation development allow him to solve customers’ problems effectively with a high degree of scientific rigour.
End-in-mind Approach
Through our end-in-mind approach we link particle science to formulation and process understanding, maximising the chance of your small molecule success
Our integrated chemical development, material science, preformulation and analytical development teams offer a holistic approach to medicines development, breaking down the barriers between drug substance and drug product.
SmartPath
SmartPath is our innovative digital tool that risk assesses your API, project, and formulation data and offers actionable mitigation strategies from our crystallisation and solid state expert, Dr Robert Dennehy.
When it comes to your API project you need to know what the risks are, the threat they pose, and how to alleviate them. SmartPath eliminates the guesswork and presents you with answers.
